Privately-held US specialty oncology pharmaceutical company Athenex on Friday announced a new collaboration to conduct a Phase 1b study that will evaluate the safety and tolerability of oraxol, Athenex’ oral form of paclitaxel.
Athenex said it will evaluate oraxol in combination with pharma major Eli Lilly (NYSE: LLY) Cyramza (ramucirumab), a vascular endothelial growth factor (VEGF) receptor 2 antagonist, in patients with advanced gastric (stomach) and esophageal cancer.
Patient enrollment, currently expected to start in 2017, is planned at sites in the USA and Asia. Athenex will be the sponsor of the clinical trial and Lilly will supply Cyramza. No financial terms of the collaboration have been disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze